Clinical Trials and Research
Studies Currently Enrolling
Age-Related Macular Degeneration
Exudative ('Wet') Age-Related Macular Degeneration
Phase III Study evaluating extended delivery of intravitreal Lucentis using a refillable implant. Sponsored by Genentech
Study evaluating intravitreal injection of hI-con1 as monotherapy or in combination with Lucentis as compared with Lucentis in patients with choroidal Neovascularization Secondary to ARMD. Sponsored by ICONIC
Study evaluating abicipar (an antiVEGF drug) as monotherapy compared with Lucentis for patients with choroidal neovascularization in AMD. Sponsored by Allergan
Non-Exudative ('Dry') Age-Related Macular Degeneration
PHASE II Multi-center, randomized, sham injection-controlled exposure-response study of Lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy
Emixustat for treatment of Geographic Atrophy. Sponsored by Acucela. NOTE THAT ENROLLMENT FOR THIS STUDY IS COMPLETED
Retinal Vein Occlusion
Ozurdex for RVO
Study evaluating Ozurdex implant for patients with macular edema due to RVO resistant to prior intravitreal injections of anti VEGF drugs. CLOSED TO FURTHER ENROLLMENT
Sponsored by Allergan.
Diabetic Macular Edema (DME)
Eylea for Diabetic Macular Edema. Sponsored by Regeneron. NOTE THAT ENROLLMENT FOR THIS IS COMPLETED.
Future Studies Involvement Scheduled. Enrollment dates Pending.
Genetic Study Investigations
Study evaluating genetics of retinal dystrophies and degenerations